Stage 4 prostate cancer, also known as metastatic prostate cancer, is the most advanced stage of the disease. At this stage, treatment typically focuses on slowing disease progression, managing symptoms, and maintaining overall well-being rather than achieving a cure.
While this diagnosis can feel overwhelming, many patients live for several years with appropriate treatment and ongoing care. Meanwhile, clinical trials and emerging therapies continue to explore new approaches to treating metastatic prostate cancer, offering additional options in certain cases.
This guide provides an overview of how stage 4 prostate cancer is defined, how it is diagnosed, common symptoms, long-term prognosis, and available treatment options to help you understand your condition and plan next steps.
What Is Stage 4 Prostate Cancer?
Stage 4 prostate cancer means the cancer has spread beyond the prostate to nearby lymph nodes or distant parts of the body, such as the bones or other organs.
According to the TNM staging system, Stage 4 prostate cancer is characterized by one or more of the following:
- Any T: The main tumour can either stay within the prostate or grow beyond it
- N1: The cancer has reached nearby lymph nodes
- M1: The cancer has spread to distant parts of the body, like the bones or other organs
- Any Grade Group or Gleason score
- Any PSA level
In simple terms, Stage 4 prostate cancer is defined by the presence of spread to lymph nodes (N1) or distant sites (M1). If the cancer has not spread to these areas (N0, M0), it is classified as Stage 3 prostate cancer or earlier.
How Stage 4 Prostate Cancer Is Diagnosed
Prostate cancer diagnosis often starts with PSA testing and digital rectal exams. While abnormal results can be an early indicator, they do not alone confirm prostate cancer.
If cancer is suspected, your doctor will then order a prostate biopsy, during which a small portion of the prostate is removed and analyzed under a microscope to confirm cancer and assign it a Gleason score.
While biopsy results determine the cancer’s Grade Group, imaging tests are used to evaluate the extent of disease and whether it has spread beyond the prostate. Conventional imaging methods such as CT scans and bone scans have traditionally been used to detect metastases, although they may have limitations in detecting smaller or early metastatic disease.
At Vitus Privatklinik, we rely on advanced magnetic resonance imaging (MRI) to detect and assess prostate tumours, along with PSMA PET/CT imaging to determine whether metastases have developed elsewhere in the body.
Other indicators, such as bone pain or organ-related symptoms, may suggest metastatic spread, but imaging tests are required to confirm whether prostate cancer has progressed to Stage 4, regardless of PSA and biopsy results.
Understanding Stage 4 Prostate Cancer Substages
| Substage | Spread | TNM Classification | Typical Focus |
| Stage 4A | Nearby lymph nodes | N1, M0 | Regional + systemic treatment |
| Stage 4B | Distant sites (bones/organs) | M1 | Systemic disease management |
Stage 4 prostate cancer is divided into substages based on how far the cancer has spread. These distinctions help differentiate between cancer that has reached nearby lymph nodes and cancer that has spread to distant parts of the body.
Prostate Cancer Stage 4A
Stage 4A prostate cancer is considered advanced with regional spread. This means that the cancer has spread to nearby lymph nodes but has not been detected in distant organs (N1, M0).
While still an advanced form of the disease, Stage 4A prostate cancer may be managed differently from Stage 4B in some cases, with treatment plans that can include a combination of systemic therapy and local treatments.
Prostate Cancer Stage 4B
Stage 4B prostate cancer is diagnosed once the disease has spread to distant parts of the body (M1). This can include the bones, distant lymph nodes, or other organs.
With a Stage 4B diagnosis, treatment typically focuses on systemic therapies to slow disease progression and manage symptoms. In some cases, clinical trials or emerging treatments may provide additional options.
Stage 4 Prostate Cancer Symptoms
At Stage 4, symptoms are more common and noticeable than in earlier prostate cancer stages. They are often caused by cancer spreading beyond the prostate, affecting other parts of the body and leading to systemic effects.
While symptoms can vary depending on where the cancer has spread, common symptoms of Stage 4 prostate cancer include:
- Fatigue
- Unexplained weight loss
- Urinary retention
- Nocturia
- Incomplete bladder emptying
- General pain or discomfort
- Weakness
- Reduced mobility
- Leg swelling
- Bone pain (particularly with bone metastases)
Other symptoms may develop depending on the location and extent of metastasis. Symptoms alone should not be used to diagnose the stage of prostate cancer.
Is Stage 4 Prostate Cancer Curable?
Because it has spread beyond the prostate, metastatic prostate cancer is generally not considered curable. Instead, the primary goal of traditional treatment options is to control cancer growth, extend life, and maintain quality of life.
With that said, many patients live for years with ongoing treatment and monitoring. Meanwhile, research is continuing to advance new approaches, and clinical trials are exploring alternative treatment options.
One such approach is immunotherapy, which helps the immune system recognize and destroy cancer cells. The immune system is currently the only known mechanism capable of identifying and targeting cancer cells throughout the body, making immunotherapy a promising area of research in metastatic prostate cancer treatment.
Stage 4 Prostate Cancer Treatment Options
Patients with Stage 4 prostate cancer have several treatment options that aim to control disease progression and manage symptoms.
At this stage, most patients receive systemic therapies that affect the whole body, such as hormone therapy, chemotherapy, targeted therapies, and certain forms of radiation. The specific approach depends on factors like the location and extent of spread, prior treatments, and overall health.
In many cases, patients receive a combination of therapies, which may be adjusted over time as the disease progresses.
Call us now on +49 (0)177 23 82 863 or get in touch using the contact form
Hormone Therapy (Androgen Deprivation Therapy)
Hormone therapy (ADT) is often the first-line treatment for advanced prostate cancer and is intended to lower testosterone levels. By reducing the hormones responsible for cancer cell growth, ADT helps slow cancer progression and maintain quality of life.
However, extended hormone therapy can lead to castration-resistant prostate cancer (mCRPC), often after 2 to 3 years. Meanwhile, treatment side effects can include hot flashes, weight gain, reduced sexual desire, body hair loss, and loss of muscle, with other long-term risks including osteoporosis.
In many cases, combination therapies like hormone therapy and chemotherapy are used to manage metastatic prostate cancer. Newer hormone blockers, called androgen receptor-targeted therapies, are often added to standard treatment and have been shown to further delay disease progression without significantly impacting daily function.
However, these approaches remain focused on systemic disease control rather than eliminating metastatic cancer, and treatment strategies are often adjusted over time as resistance develops.
Chemotherapy
Chemotherapy is often used to treat metastatic prostate cancer when hormone therapy is no longer effective, or in combination with hormone therapy in some cases. During treatment, chemotherapy drugs, such as docetaxel (Beizray, Docivyx, Taxotere), cabazitaxel (Jevtana) and other medicines, are administered through a vein, typically once every three weeks.
These chemotherapy drugs target rapidly dividing cells throughout the body, including both cancerous and healthy cells. As a result, chemotherapy often triggers systemic side effects that can include fatigue, nausea, and increased risk of infections due to lower white blood cells.
Targeted Therapy
Targeted therapy is used in some cases of metastatic prostate cancer, particularly in patients with specific genetic mutations identified through biomarker testing. These treatments work by targeting processes that cancer cells rely on to grow and survive.
In advanced prostate cancer, the most common targeted therapies are PARP inhibitors, which may be used in patients with certain DNA repair gene mutations identified through biomarker testing.
Side effects of targeted therapy can include fatigue, nausea, loss of appetite, and increased risk of infections.
Radiation Therapy
Radiation therapy can be an option for stage 4 prostate cancer and can be applied via radiopharmaceuticals or as external beam radiation.
During radiopharmaceutical treatments, medications like Pluvicto target specific proteins on prostate cancer cells (such as PSMA) to deliver radiation therapy, allowing for a more targeted treatment approach.
External beam radiation therapy uses high-energy rays to deliver radiation to specific areas of the body, including metastases that have spread to the bones. In most cases, radiation therapy is used to alleviate symptoms and reduce pain caused by metastatic prostate cancer.
Immunotherapy and Focal Therapy Combination Treatments
Despite being an immunologically cold tumour, immunotherapy can be effective for metastatic prostate cancer when combined with focal therapies, particularly electroporation-based treatments like electrochemotherapy (ECT) and irreversible electroporation (IRE).
As non-thermal focal therapies, ECT and IRE destroy prostate cancer cells without the extreme heating or freezing that comes with HIFU or cryotherapy. This allows for the preservation and release of prostate-specific tumour antigens, which support immune recognition.
Immunotherapy is then used to support the body’s immune response, helping the immune system recognize and target cancer cells that have spread outside of the prostate, including to lymph nodes and distant organs.
This combination approach aims to treat prostate cancer using targeted focal therapy, while also supporting the body’s ability to identify and target metastatic cancer cells that may have developed outside the prostate.
Choosing the Right Treatment for Stage 4 Prostate Cancer
Unlike earlier stages, treatment for Stage 4 prostate cancer is not based on a single decision but is an ongoing process that evolves over time. As the disease progresses and responds to therapy, treatment plans are often adjusted to maintain control of the cancer and preserve quality of life.
When determining the most appropriate approach, several factors are considered:
- Extent and location of metastasis
- Cancer response to prior treatments
- Overall health and ability to tolerate treatment
- Symptom burden and quality-of-life priorities
- Patient preferences and available support systems
- Biomarker identification and genetic mutations that may guide targeted therapies
For more information about treating advanced prostate cancer, you can speak with the team at Vitus Privatklinik.
Stage 4 Prostate Cancer Prognosis and Survival Rates
The prognosis for metastatic prostate cancer is generally more serious than in earlier stages.
Survival rates can vary widely depending on individual factors such as PSA levels, Gleason score, extent of metastases, and overall health. The 5-year relative survival rate for distant prostate cancer is approximately 37.9%.
It is important to understand that survival statistics are based on large population averages and do not predict individual outcomes. Some patients experience more aggressive disease progression, while others respond well to treatment and live for many years with stable disease.
With proper management and care, many patients are able to manage the disease over time, and ongoing research continues to explore new treatment approaches through clinical trials.
Life With Stage 4 Prostate Cancer
A metastatic prostate cancer diagnosis can feel overwhelming, and it’s normal to have questions about what comes next. While this stage of the disease is more advanced, many patients live for years with ongoing treatment, monitoring, and supportive care.
You do not have to go through this alone. Working with an experienced care team can help you better understand your options, manage side effects, and make informed decisions at each stage of treatment.
If you would like to review your diagnosis or explore your treatment options in more detail, you can speak with the team at Vitus Privatklinik for personalized support.
Frequently Asked Questions
Yes, Stage 4 prostate cancer is treatable. While it is not typically curable, a range of therapies can be used to slow disease progression, manage symptoms, and extend survival. Treatment plans often involve a combination of approaches and may be adjusted over time based on how the cancer responds.
Symptoms can vary depending on where the cancer has spread, but may include fatigue, bone pain, urinary difficulties, weight loss, and reduced mobility. In some cases, symptoms are mild at first and become more noticeable as the disease progresses.
Stage 4 prostate cancer spreads when cancer cells move beyond the prostate to other parts of the body. These cells can travel through the bloodstream or lymphatic system and most commonly form new tumours in the bones or lymph nodes. The pattern of spread influences both symptoms and treatment decisions.
Treatment options typically include hormone therapy, chemotherapy, targeted therapies, radiation, and, in some cases, immunotherapy. The specific combination depends on factors such as the extent of metastasis, prior treatments, and overall health.
Prognosis varies depending on individual factors such as cancer aggressiveness and extent of spread. While survival rates are lower than in earlier stages, many patients live for several years with appropriate treatment and ongoing care.
Stage 4 prostate cancer is generally not considered curable. However, it can often be managed for extended periods with metastatic prostate cancer treatment focused on slowing disease progression and maintaining quality of life.
- American Joint Committee on Cancer (AJCC). AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Current version. Available at: https://www.nccn.org. Accessed March 2026.
- National Cancer Institute. SEER Cancer Stat Facts: Prostate Cancer. Available at: https://seer.cancer.gov/statfacts/html/prost.html. Accessed March 2026.
- Guenther E, Klein N, Zapf S, et al. Prostate cancer treatment with Irreversible Electroporation (IRE): safety, efficacy and clinical experience in 471 treatments. PLoS One. 2019;14(4):e0215093. Published 2019 Apr 15. doi:10.1371/journal.pone.0215093.
- Stevanovic M, Heringer M, Hjouj M, Zanasi A, Terlizzi F, Stehling MK. Prostate cancer treatment with electrochemotherapy (ECT): safety, efficacy and clinical experience in 144 patients. Radiol Oncol. 2025;59(4):597–606. Published 2025 Dec 16. doi:10.2478/raon-2025-0061.